Abstract
Subclinical and clinical bleomycin-induced pulmonary toxicity (BIP) were investigated retrospectively in 109 patients with non-Hodgkin's lymphoma treated by combination chemotherapy containing bleomycin. A decrease in carbon monoxide diffusing capacity (DLCO) was found in 12.8% of patients. The cumulative risk of abnormal DLCO increased with the increasing total cumulative dose of bleomycin. No significant difference in the rate of BIP was observed between patients receiving bleomycin/Adriamycin/cyclophosphamide/vincristine/prednisone (BACOP; bleomycin given at 10 mg/m2 for 4 weeks) and bleomycin/Adriamycin/cyclophosphamide/vincristine/dexamethasone/methotre xate/ folinic acid (m-BACOD; bleomycin given at 4 mg/m2 for 3 weeks, methotrexate given at 200 mg/m2. Monitoring for subclinical BIP should be considered in patients with non-Hodgkin's lymphoma even if only a low dose of bleomycin was given in the presence of other chemotherapeutic agents.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bleomycin / administration & dosage
-
Bleomycin / adverse effects*
-
Chi-Square Distribution
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Dexamethasone / administration & dosage
-
Dexamethasone / adverse effects
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Humans
-
Leucovorin / administration & dosage
-
Leucovorin / adverse effects
-
Lung / drug effects*
-
Lung / physiopathology
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / physiopathology
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects
-
Middle Aged
-
Prednisone / administration & dosage
-
Prednisone / adverse effects
-
Pulmonary Diffusing Capacity / drug effects
-
Respiratory Function Tests
-
Retrospective Studies
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
Substances
-
Bleomycin
-
Vincristine
-
Dexamethasone
-
Doxorubicin
-
Cyclophosphamide
-
Leucovorin
-
Prednisone
-
Methotrexate
Supplementary concepts
-
CHOP-B protocol
-
M-BACOD protocol